AUTHOREA
Log in
Sign Up
Browse Preprints
LOG IN
SIGN UP
Diogo Mota
Public Documents
3
August 01, 2022
Real-world evidence on the risk of cancer with anti-IL-5 and anti-IL-4Ra biologicals
Diogo Mota, Tiago Rama, André Moreira, et al.
June 29, 2021
Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's Vig...
Diogo Mota, Tiago Rama, Milton Severo, et al.
April 13, 2021
Potential cancer risk with omalizumab: a disproportionality analysis of the WHO’s Vig...
Diogo Mota, Tiago Rama, Milton Severo, et al.